Table 11, Disaggregated Summary of CADTH’s Base Case - Pharmacoeconomic Report: Ofatumumab (Kesimpta)

	Undiscounted	Discounted
Ofatumumab	30.75	$155,326	$791	$798,433	$303	$25,239	$980,092	6.19
Ocrelizumab	30.75	$173,629	$839	$790,006	$305	$25,440	$990,218	6.33
Alemtuzumab	30.75	$101,084	$1,521	$779,501	$334	$24,705	$907,145	6.51
Cladribine	30.75	$84,881	$937	$797,400	$311	$25,888	$909,418	6.20
Natalizumab	30.75	$233,251	$1,261	$791,043	$303	$25,331	$1,051,190	6.31
Fingolimod	30.75	$138,829	$996	$813,176	$294	$26,286	$979,580	5.94
Teriflunomide	30.75	$103,387	$868	$834,105	$274	$27,583	$966,216	5.59
Dimethyl fumarate	30.75	$128,455	$970	$814,834	$288	$26,585	$971,132	5.91
Glatiramer acetate	30.75	$59,965	$777	$823,460	$290	$27,420	$911,911	5.76
Avonex	30.75	$113,917	$1,073	$818,279	$278	$28,297	$961,843	5.83
Rebif 22	30.75	$95,482	$1,024	$821,243	$251	$27,885	$945,885	5.79
Rebif 44	30.75	$118,299	$1,033	$825,287	$255	$27,491	$972,365	5.73
Betaseron	30.75	$103,777	$1,389	$824,329	$527	$27,563	$957,585	5.73
Extavia	30.75	$97,882	$1,389	$824,509	$527	$27,577	$951,883	5.73
BSC	30.75	$0	$0	$844,344	$0	$29,467	$873,811	5.42

Undiscounted

Discounted

Intervention

Life-years

Drug costs (including re-treatment)

Administration and monitoring costs

Health- state costs

Adverse event costs

Relapse costs

Total cost

QALYs

Ofatumumab

30.75

$155,326

$791

$798,433

$303

$25,239

$980,092

6.19

Ocrelizumab

30.75

$173,629

$839

$790,006

$305

$25,440

$990,218

6.33

Alemtuzumab

30.75

$101,084

$1,521

$779,501

$334

$24,705

$907,145

6.51

Cladribine

30.75

$84,881

$937

$797,400

$311

$25,888

$909,418

6.20

Natalizumab

30.75

$233,251

$1,261

$791,043

$303

$25,331

$1,051,190

6.31

Fingolimod

30.75

$138,829

$996

$813,176

$294

$26,286

$979,580

5.94

Teriflunomide

30.75

$103,387

$868

$834,105

$274

$27,583

$966,216

5.59

Dimethyl fumarate

30.75

$128,455

$970

$814,834

$288

$26,585

$971,132

5.91

Glatiramer acetate

30.75

$59,965

$777

$823,460

$290

$27,420

$911,911

5.76

Avonex

30.75

$113,917

$1,073

$818,279

$278

$28,297

$961,843

5.83

Rebif 22

30.75

$95,482

$1,024

$821,243

$251

$27,885

$945,885

5.79

Rebif 44

30.75

$118,299

$1,033

$825,287

$255

$27,491

$972,365

5.73

Betaseron

30.75

$103,777

$1,389

$824,329

$527

$27,563

$957,585

5.73

Extavia

30.75

$97,882

$1,389

$824,509

$527

$27,577

$951,883

5.73

BSC

30.75

$844,344

$29,467

$873,811

5.42

From: Appendix 4, Additional Details on the CADTH Reanalysis

Cover of Pharmacoeconomic Report: Ofatumumab (Kesimpta)

Pharmacoeconomic Report: Ofatumumab (Kesimpta): (Novartis Pharmaceuticals Canada Inc.): Indication: Multiple Sclerosis, Relapsing-Remitting [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2021 Apr.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Table 11Disaggregated Summary of CADTH’s Base Case